Short DAPT Eligibility Calculator

Clinical setting
Select the scenario that best describes the current patient with acute coronary syndromes who has undergone percutaneous coronary intervention with a contemporary drug eluting stent.

Patient has completed at least 1 month of dual antiplatelet therapy without recurrent ischemia or stent thrombosis

No major bleeding event during the first month of dual antiplatelet therapy

Bleeding risk
Indicate whether the patient meets Academic Research Consortium high bleeding risk status using major and minor criteria after percutaneous coronary intervention.

Patient meets high bleeding risk definition at least 1 major or at least 2 minor criteria according to Academic Research Consortium high bleeding risk criteria

Ischemic and anatomic risk factors that may favor standard or longer dual antiplatelet therapy
Select all that are present.

Complex coronary anatomy or complex percutaneous coronary intervention such as left main or proximal left anterior descending involvement bifurcation stenting with two stents long total stent length multivessel stenting or chronic total occlusion

Large myocardial infarction or left ventricular systolic dysfunction for example ejection fraction less than about forty percent

Recurrent myocardial infarction recurrent ischemia or stent thrombosis since the index percutaneous coronary intervention

Planned staged percutaneous coronary intervention or coronary artery bypass graft surgery that still requires full dual antiplatelet therapy

Other strong indication for extended dual antiplatelet therapy such as prior stent thrombosis on adequate therapy or very high burden of diffuse coronary artery disease

Concomitant therapies
Select if present.

Patient requires chronic oral anticoagulant therapy for atrial fibrillation venous thromboembolism or other indication

Short DAPT Eligibility Calculator Explanation and Clinical Context
This tool is designed for patients with acute coronary syndromes who have undergone percutaneous coronary intervention with contemporary drug eluting stents and are treated with dual antiplatelet therapy that combines aspirin and an oral P2Y12 inhibitor. The 2025 acute coronary syndromes guideline identifies a default strategy of about 12 months of dual antiplatelet therapy in patients who are not at high bleeding risk and emphasizes that shorter or longer durations should be tailored to the balance between bleeding and ischemic risk.

Evidence from randomized trials such as MASTER DAPT and other studies of abbreviated dual antiplatelet strategies suggests that in patients at high bleeding risk who have completed about 1 month of dual antiplatelet therapy without recurrent ischemic events transition to single antiplatelet therapy can reduce clinically relevant bleeding without a clear excess of major adverse cardiovascular events. The guideline therefore supports consideration of abbreviated regimens in carefully selected high bleeding risk patients particularly when coronary anatomy is not highly complex and when there has been no recurrent myocardial infarction stent thrombosis or unstable ischemia.

This calculator uses a qualitative rule based approach that combines Academic Research Consortium high bleeding risk status completion of at least 1 month of dual antiplatelet therapy early bleeding tolerance and the presence or absence of ischemic and anatomic features that usually favor standard or longer duration dual antiplatelet therapy. The output categorizes the patient profile as favoring a short duration strategy suggesting that short dual antiplatelet therapy is possible but requires caution or favoring standard duration. The result does not replace formal risk scores such as PRECISE DAPT or DAPT score and does not supersede local protocols. Coronary angiographic details multidisciplinary discussion and patient preference are essential in final decision making.

Clinicians should also integrate the presence of a chronic indication for oral anticoagulant therapy which often favors earlier transition to a single antiplatelet agent together with anticoagulant therapy to limit bleeding risk. Regular reassessment of bleeding and ischemic risk during follow up is important because these risks can change over time with new comorbid conditions procedures or events.

Reference
Rao SV O Donoghue ML Ruel M et al. 2025 guideline for the management of patients with acute coronary syndromes. Journal of the American College of Cardiology. 2025 85 22 2135 2237.
Valgimigli M Frigoli E Heg D et al. Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk. New England Journal of Medicine. 2021 385 1643 1655.
Urban P Mehran R Colleran R et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019 140 240 261.

Discussion

No discussions yet. Be the first to comment.

Short DAPT Eligibility Calculator

ACS Early Rule Out Pathway Tool

PARIS Bleeding Risk Score Calculator

CRUSADE Bleeding Risk Score Calculator

NSTEMI Early Angiography Benefit Estimator Tool

TIMI Risk Score for STEMI Calculator

Right Ventricular Infarction ECG V4R Assessment Tool

Initial ACS ECG Triage 10 Minutes Action Tool

PURSUIT Risk Score Mortality Calculator

Stress Test versus Coronary CT Before Discharge Pathway Tool

ACS Short Term Mortality Prediction Tool

Discussion

Create Note

My Notes

Report this Tool